Background We previously reported that dietary glucosylceramides show cancer-prevention activity in a mouse xenograft model of human head and neck cancer cells (SCCKN). However, the mechanism was unclear. Ceramides, metabolites of glucosylceramides, induce apoptotic cell death in various malignancies. Here, we investigated the inhibitory effects of dietary glucosylceramides on tumor growth in vivo and in vitro. Methods SCCKN were subcutaneously inoculated into the right flanks of NOD/SCID mice. Mice were treated with or without dietary glucosylceramides (300 mg/kg) daily for 14 consecutive days after confirmation of tumor progression. Microvessel areas around the tumor were assessed by hematoxylin-eosin staining and immunohistochemistry of CD31, and, as markers for angiogenesis, protein levels of VEGF, VEGF receptor-2, and HIF-1a were assessed by Western blotting. Mass spectrometry was performed to measure the levels of sphingolipids in mouse serum after treatment with dietary glucosylceramides.
Introduction
Head and neck squamous cell carcinoma (HNSCC) is the sixth most prevalent neoplasm in the world [1] . Historically, most advanced and resectable HNSCCs have been treated with surgery followed by postoperative radiotherapy and chemotherapy. However, these therapies result in significant cosmetic deformity, as well as functional deficits in speech and swallowing. In recent decades, combined modality approaches have been developed, and chemotherapy is a major component of these treatment approaches for improving survival in patients [2] . Several new anticancer agents have been introduced into clinical practice, including molecular targeted agents such as epidermal growth factor receptor inhibitors. Despite these new treatment options, survival rates for HNSCC have not improved significantly in decades [1, 3] . The development of novel therapeutics is therefore needed.
In our previous study, we found that dietary glucosylceramides (Glu-Cer) have anti-tumor activity in an HNSCC xenograft mouse model [4] . Glu-Cer were isolated from rice bran and the main chemical constituent is 1-O-b-glucosyl-N-2 0 -hydroxy-arachidoyl-4,8-sphingadienine. It has been reported previously that orally administrated Glu-Cer improves skin barrier function [5] . However, the mechanism by which dietary Glu-Cer exerts its biological functions in mice remains unclear. In vivo, intraperitoneally injected Glu-Cer inhibited the growth of inoculated MH134 hepatic cell carcinoma and the infiltration of EL4 cells to the liver by the activation of NKT cells in mice [6, 7] . Since Glu-Cer was administrated orally in our previous study, it is unclear whether dietary Glu-Cer activated NKT cells as with intraperitoneal injection. In vitro, treatment with GluCer has been shown to inhibit NADPH oxidase and induce chemoresistance in human SH-SY5Y neuroblastoma cells [8] . A synthesizing enzyme of Glu-Cer, Glu-Cer synthase, is activated in malignant cells when they show chemoresistance. Thus, Glu-Cer alone may play a role in the regulation of cell growth. On the other hand, in vivo dietary GluCer may be metabolized into its constituent components, such as sphingoid bases, through glucosylceramidase and ceramidase in the gut or intestinal epithelial cells [9, 10] . After the digestion of Glu-Cer in the gut, it may be that sphingoid bases stimulate the synthesis of ceramides in intestinal epithelial cells, and ceramides are then delivered into the bloodstream [10, 11] . Ceramides are known to be a bioactive lipid mediator, with involvement in cell growth, differentiation, migration, senescence, and cell death [12] [13] [14] . Ceramide induces not only apoptotic cell death but also autophagic or necrotic cell death [15] [16] [17] . However, at present there are no reports clarifying the metabolic changes caused by dietary plant Glu-Cer in mice tissues.
As a cause of cell death in vivo, it has been reported that ceramide inhibits angiogenesis in zebrafish through a decrease of vascular endothelial growth factor (VEGF) expression in endothelial cells [18] . Tumors need abnormal cell growth and sufficient blood flow, and this is especially true of most HNSCC tumors which require rich blood flow. Several studies have suggested that tumor angiogenesis is associated with tumor progression and outcome in a number of malignancies [19] [20] [21] [22] [23] . Blood supply to the tumors is especially necessary under hypoxic and low pH conditions. Angiogenesis is mainly driven by VEGF, which belongs to a subfamily of secreted, dimeric glycoproteins of approximately 40 kDa, named platelet-derived growth factor (PDGF). Expression of VEGF mRNA is regulated by the transcription factor HIF-1a, which plays a key role in protecting tumor cells from hostile conditions. Overall, tumor vascularization through VEGF expression relies partly on the stable expression of HIF-1a. The activation of HIF-1a is mandatory for several responses, including apoptosis, cell survival, cell adhesion, and angiogenesis [24, 25] . VEGF is a potent, multifunctional cytokine that exerts several important and possibly independent actions on vascular endothelium [26] . Because of these effects, VEGF is often the first-choice target of anti-angiogenic therapies tested in clinical trials [27] . All VEGF molecules transduce signals by binding to VEGF receptors (VEGFR)-1, -2, and -3. Of them, VEGFR-2 is the key molecule for VEGF signaling in the tumor microenvironment, affecting vascular permeability and endothelial cell proliferation [28, 29] . VEGFR-2 expression has been found to increase in vessels around tumor cells, because VEGFR-2 expression is associated with the beginning of vasculogenesis [30] . These findings suggest an autocrine loop for VEGF/VEGFR-2 in HNSCC growth. Several cascades emanating from the VEGF/ VEGFR-2 complex regulate critical angiogenic responses of endothelial cells [31] . However, at present it is unknown whether Glu-Cer induces the generation of ceramides or is involved in the regulation of angiogenesis through the VEGF/VEGFR-2 axis via regulation of HIF-1a.
The purpose of the present study was to determine whether Glu-Cer and its metabolite ceramide regulate the functions of VEGF, VEGFR-2, and HIF-1a. Accordingly, we investigated the levels of angiogenesis after treatment with dietary Glu-Cer and the levels of VEGF, VEGFR-2, and HIF-1a by immunohistochemistry and Western blotting in a mouse xenograft model as well as an in vitro cell culture system. We also determined whether the levels of sphingolipids, including ceramides, were changed in mouse serum after oral administration of Glu-Cer. Our results showed that dietary Glu-Cer suppressed the growth of head and neck tumors through the inhibition of pro-angiogenic signals such as VEGF, VEGFR-2, and HIF-1a due to an increase in sphingosine-based ceramide.
Methods

Tumor cell xenografts
The SCCKN cell line, established from tongue squamous cell carcinoma, was obtained from RIKEN BRC Cell Bank (Tsukuba, Japan). SCCKN cells were grown in RPMI1640 supplemented with 10 % fetal bovine serum, 100 U/mL penicillin, and 100 lg/mL streptomycin. The cell cultures were maintained in a humidified atmosphere of 5 % CO 2 / 95 % air at 37°C. Male and female NOD/SCID mice (8-10 weeks of age) were obtained from a breeding colony of the animal experimental institution at the Tottori University Hospital, Tottori. The mice were housed in a highefficiency, particulate air-filtered, positive-pressure room kept at a temperature of 24 ± 2°C and 55 % humidity. Tumor cell xenografts were obtained as previously described [4] . After confirmation of successful implantation (1 month after inoculation), mice were randomly divided into two groups: a non-medicated group [G(-) group] and a medicated group [G(?) group]. Each group contained 7 mice. We discarded mice bearing a tumor less than 5 mm in diameter. Glu-Cer (1-O-b-glucosyl-N-2 0 -hydroxyarachidoyl-4,8-sphingadienine) was extracted from rice bran at the Oryza Oil & Fat Chemical Company (Aichi, Japan) with a purity of 8 %. The maximum tolerated dose and treatment dose had already been determined by our previous study [4] . The protocols were approved by the Animal Research Committee at Tottori University (approval numbers 10-Y-46, 10-Y-65, and 12-Y-48).
Treatment
Mice were treated with Glu-Cer (300 mg/kg) daily for 14 consecutive days. Glu-Cer suspended in cellulose was administered orally using a disposable feeding needle (0.9 9 38 mm) (EXEC Inc., Tokyo, Japan). Solutions were delivered after insertion of the feeding tube distal to the upper esophageal sphincter to prevent aspiration of solution during oral gavage. In the G(-) group, mice were administered cellulose only.
Tumor measurement
Tumors were measured twice a week in two dimensions using calipers. Tumor tissue volume was calculated using the formula: length 9 (width) 2 9 0.52.
Microvessel quantification
Slides were stained with hematoxylin and eosin and were examined by light microscopy, focusing on ten areas that were dense with active tumors. Microvessels were counted at a magnification of 9400. For xenograft tissues, microvessel density was measured as the decolorized area, which was calculated using Image J (National Institutes of Health, Bethesda, MD, USA) and expressed as a percentage. No counts were performed in areas of necrosis and vacuolization.
Immunohistochemical staining Double immunostaining for CD31 as a mature endothelial marker and for NG2 as a pericyte marker was performed. From the frozen tumor tissues, cryostat sections (10 lm thick) were made and fixed in acetone for 10 min. After washing with PBS, the sections were preincubated with a solution containing 10 % normal goat serum (NGS) for 30 min to reduce nonspecific staining, after which they were incubated overnight at 4°C with primary antibody for CD31 (anti-CD31, diluted 1:200; BD Biosciences, San Jose, CA, USA). Following this, the sections were rinsed and incubated with secondary antibody for CD31 (anti-rat IgG, diluted 1:1,000; Molecular Probes, Carlsbad, CA, USA). After being rinsed again, the sections were incubated with 10 % NGS for 30 min. They were then incubated for 90 min with primary antibody for NG2 (anti-NG2 antibody, diluted 1:100; Chemicon, Millipore, Billerica, MA, USA), rinsed, and then incubated for 60 min with secondary antibody for NG2 (anti-rabbit IgG, diluted 1:500; Molecular Probes). In the same procedure, double immunostaining for CD31 and for VEGFR-2 or HIF-1a was performed. We used the primary antibody for VEGFR-2 (anti-Flk-1 antibody, diluted 1:50; Chemicon, Millipore) and HIF-1a (Novus Biologicals, Littleton, CO, USA) instead of that for NG2.
Western blot analysis in vivo
Tissues with xenografted cancer cells were harvested and cut into 2 mm squares containing their surface. They were then washed with ice-cold PBS and resuspended in RIPA lysis buffer containing 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.25 % deoxycholic acid, 1 % NP-40, 1 mM EDTA (Millipore), 0.1 % SDS, and Complete EDTA-free Protease Inhibitor Cocktail Tablets (Roche, Basel, Switzerland). After sonication, the tissue suspension was left on ice for 30 min, and the lysate was centrifuged at 3,000g for 10 min at 4°C. Supernatant proteins (20 lg) were electrophoresed on a 10 % or 15 % (w/v) SDS-polyacrylamide gel and transferred to nitrocellulose membranes (Bio-Rad, Hercules, CA, USA). The membrane was blocked with PBS containing 5 % (w/v) skim milk and 0.1 % (v/v) Tween 20 for 60 min at room temperature and then incubated with antibodies against VEGF (Santa Cruz Biotechnology, Santa Cruz, CA, USA), VEGFR-2 (Thermo Fisher Scientific, Waltham, MA, USA), HIF-1a (Novus Biologicals), or actin (Santa Cruz Biotechnology) for 60 min. After three washes with PBS containing 0.1 % (v/v) Tween 20, the membrane was incubated with horseradish peroxidase-conjugated secondary antibody (Promega, Madison, WI, USA) for 60 min. After washing, protein detection was performed using ECL Western blotting detection reagents (Amersham Pharmacia Inc., Buckinghamshire, UK) according to the manufacturer's protocol.
Lipid extraction
Lipid extraction and quantification were performed as described by Bielawski et al. [32] . We measured the blood levels of sphingolipids (sphingosine-based and sphingadienine-based) in Glc-Cer-treated mice (n = 3) after 21 days of medication. Two mL of isopropanol/water/ethylacetate (30:10:60) and 50 lL of internal standards were added to a cell pellet or a tissue homogenate. The mixture was vortexed, sonicated, and then centrifuged to collect supernatant. After the extraction step was repeated, the supernatants were combined and dried under a nitrogen stream. The dried residue was redissolved in 150 lL of the mobile phase B. Lipids were separated on a Spectra C8SR column (150 9 3 mm, 3 lm) using an Agilent 1100 HPLC system. Chromatography was performed at a flow rate of 0.5 mL/min using a gradient of mobile phase A (2 mM ammonium formate aqueous solution containing 0.2 % formic acid) and B (1 mM ammonium formate in methanol containing 0.2 % formic acid). The LC system was coupled to a TSQ7000 mass spectrometer equipped with an electrospray ionization source. The LC gradient elution and the tandem mass spectrometry parameters were set according to the method described by Bielawski et al. [32] .
Western blot analysis in vitro
We examined the angiogenic factors in SCCKN and UV$2 cells. UV$2 is a murine vascular endothelial cell line obtained from RIKEN BRC Cell Bank (Tsukuba, Japan). They were treated with C6-Cer (D-erythro-C6-dihydroceramide; Matreya LLC, Pleasant Gap, PA, USA), which is a metabolite formed by dietary Glu-Cer, dissolved in RPMI1640 supplemented with 10 % fetal bovine serum for 12 h. The remainder of the protocol was the same as for that in vivo.
Statistical analysis
The results are shown as mean ± SE. Statistical comparisons between the G(-)and G(?) groups were performed using the Student t test or Mann-Whitney U-test.
Results
Inhibition of HNSCC tumor growth by dietary glucosylceramides in a xenograft model
First, we performed reproducibility experiments after our previous study, and we observed whether tumors could regrow after the treatment. As shown in Fig. 1 , in the G(-) group, the mean volume of SCCKN xenografted tumors at day 1 was 97.76 mm 3 . As they gradually increased, the mean volume at 28 days after treatment with the cellulose solution was 342.75 mm 3 , about three times the size compared to day 1. On the other hand, in the G(?) group, tumors remained approximately the same size for 2 weeks, and they did not shrink after we stopped medication.
By examining the hematoxylin-and-eosin-stained slides, we calculated the microvessel density. In the G(-) group, microvessels were located with connective tissue and penetrated inside the xenograft (Fig. 2a) . The mean area was 8.32 %. In the G(?) group, microvessels were located mainly on the surface of the tumors (Fig. 2b) . The mean area was 2.65 %. There was a statistically significant difference between the two groups (p \ 0.01) (Fig. 2c) .
To evaluate the pattern of angioinvasion, two different antibodies were used for determinations of vessels and pericytes (Fig. 3a) . Almost all vessels in both groups were surrounded by pericytes, so we concluded that they were mature. The blood vessels appeared netlike in the G(-) xenografts. On the other hand, almost all of the blood vessels appeared around the xenografts in the G(?) group.
VEGF, VEGFR-2, and HIF-1a expressions in vivo
In the immunohistochemical stainings of VEGF, VEGFR-2, and HIF-1a, we determined where each signal and receptor was distributed. In G(-), VEGF expression was increased in almost all cells in the tumors (Fig. 3b) . VEGFR-2 expression was increased in endothelial cells and in the tumor cells around the area of vessel growth (Fig. 3c) . HIF-1a expression was increased in the avascular area in the tumors (Fig. 3d) . In G(?), the expressions of the signals and receptor were decreased ( Fig. 3b-d) . In addition, VEGF, VEGFR-2, and HIF-1a expression levels were analyzed by Western blotting. VEGF and HIF-1a expression levels in the G(-) group increased by at least twice those in G(?). For VEGFR-2, it was 4.5 times that in G(?). There were statistically significant differences between the G(-) and G(?) groups (p \ 0.05) for all proteins (Fig. 4a) .
Measurement of ceramide concentrations
Ceramides are synthesized by three pathways, the de novo pathway, the SMase pathway, and the salvage pathway [14, 33, 34] . By detecting differences in their bases, we can know by which pathway ceramides were synthesized. Sphingosine-based ceramides are synthesized through these pathways, while sphingadienine-based ceramides cannot be synthesized in vivo. To determine whether GluCer was absorbed through the intestines into the body, we compared the blood levels of sphingosine-based and sphingadienine-based ceramides in the G(-) and G(?) groups. In the G(?) group, the blood levels of sphingosinebased ceramides were increased (Fig. 5) .
VEGF, VEGFR-2, AND HIF-1a expressions in vitro
Following the results of mass spectrometry (Fig. 5) , we examined the expression levels of angiogenic factors in vitro, with the use of C6-Cer. Concentrations of 0 and 10 lM were used to treat SCCKN cells and UV$2 cells for 12 h each. In SCCKN cells, the levels of VEGF, VEGFR-2, and HIF-1a had statistically significant differences between the G(-) and G(?) groups (p \ 0.05) (Fig. 4b) . In UV$2 cells, there were also significant differences (Fig. 4c) . In both cell lines, VEGF and HIF-1a expression levels followed similar tendencies, and the VEGFR-2 expression level was especially suppressed by treatment with C6-Cer. 
Discussion
In our previous study, we demonstrated that oral administration of Glu-Cer had anti-tumor activity in a HNSCC xenograft model [4] . As shown in Figs. 1 and 2 , dietary Glu-Cer suppressed the volume of inoculated HNSCC through the inhibition of angiogenesis. When we measured microvessels in the tumors, a significant increase in the vessel area was detected on the surface (Fig. 2) . Based on the results of the microvessel density assays and immunohistochemical staining for tumor progression areas (Figs. 2 and 3a) , oral administration of Glu-Cer significantly affected blood vessel formation. We therefore focused on angiogenesis as the mechanism by which oral administration of Glu-Cer affects tumor growth. We studied the anti-angiogenic effect of Glu-Cer in a SCCKN xenograft model by examining the inhibition of angiogenesis signals. In vivo, oral administration of Glu-Cer appeared to suppress VEGF, VEGFR-2, and HIF-1a in the tumor progression areas. In the G(?) group, the expressions of VEGF and HIF-1a decreased in the tumor cells (Fig. 3b, d ). On the other hand, it is clear that VEGFR-2 expression mainly decreased in the vessel area stained by CD31 (Fig. 3c) . To confirm the results of immunohistochemistry, the protein levels of VEGF, VEGFR-2, and HIF-1a in the tumors were investigated. By Western blot analysis, we found that dietary Glu-Cer induced inhibition of VEGF, VEGFR-2, and HIF-1a in the mouse xenograft tumors (Fig. 4a) . These data suggest that the tumor cells at the margin of the tumor can respond to hypoxic conditions at first by increasing HIF-1a to activate VEGF, but that Glu-Cer treatment inhibited the production of VEGF through inhibition of HIF-1a. Asano et al. [35] demonstrated that an immunoneutralizing monoclonal antibody against VEGF inhibits the growth of fibrosarcoma in a xenograft model. In HNSCC, this is the first report to show anti-angiogenic effects through inhibition of HIF-1a by dietary Glu-Cer. How did dietary Glu-Cer induce the inhibition of HIF1a/VEGF and VEGFR-2? Dietary Glu-Cer is metabolized by glucosylceramidase and ceramidase into its constituent components, including sphingoid bases, in the gut or in intestinal epithelium. Ceramides may then be resynthesized in intestinal epithelial cells, and enter the bloodstream [10, 11] to affect cellular activities [12] [13] [14] . To detect changes in sphingolipids, including ceramide and sphingoid bases after administration of Glu-Cer, the amount of sphingolipids in the serum was investigated. When we measured sphingolipids levels by mass spectrometry (LC/MS/MS), sphingosine-based ceramide significantly increased, suggesting that plant Glu-Cer stimulated the synthesis of animal-type ceramides, because (pmol/50µl) (pmol/50µl) (pmol/50µl) Fig. 5 Blood levels of sphingolipids. We measured the blood levels of sphingolipids (sphingosine-based and sphingadienine-based) in GlcCer-treated mice (n = 3) after 21 days of medication. G(-) not medicated with Glu-Cer, G(?) medicated with Glu-Cer. In the G(?) group, the blood levels of sphingosine-based ceramide were increased. *p \ 0.05 plant-derived Glu-Cer has sphingadienine-type sphingoid bases instead of sphingosine-based ceramide (Fig. 5) . Therefore, to confirm the effects of sphingosine-based ceramide on angiogenesis, we treated tumor (SCCKN) and epithelial (UV$2) cells with cell-permeable C6-Cer in vitro to investigate its effect on the expression of angiogenic factors such as VEGF, VEGFR-2, and HIF-1a [10, 11] . Our results showed that ceramide was responsible for the inhibition of VEGF, VEGFR-2, and HIF-1a at the protein level (Fig. 4b, c) . We previously reported that a short-chain ceramide, N-acetyl-ceramide (C2-ceramide), inhibits the expression of VEGF in human umbilical vein endothelial cells (HUVEC) [18] . Bansode et al. [36] reported that ceramide inhibits endothelial tube formation of HUVEC, by affecting the expression of VEGF in breast cancer. To the best of our knowledge, an inhibitory effect of ceramide on HIF-1a has never been reported. The mechanism by which ceramide regulates transcription factor HIF-1a requires more investigation. Sphingosine-1-phosphate (S1P), which is a counterpart of ceramide in cell death and proliferation, is well known as a stimulant of angiogenesis [37] . After treatment with dietary Glu-Cer, the serum levels of S1P did not change significantly (data not shown), suggesting that serum S1P may not play a role in angiogenesis in this xenograft model. As for why sphingadienine-based ceramides were not increased, it may be because P-glycoprotein contributes to the selective absorption of sphingosine from dietary sphingolipids in the digestive tract [38] . Our results are consistent with the results reported by Sugawara et al. [39] . However, it is unclear whether dietary Glu-Cer activates the intrinsic ceramide synthesis pathway to change sphingoid base to ceramide or stimulates another signaling pathway to inhibit angiogenesis. The in vivo mechanism by which the ceramide pathway is activated by dietary Glu-Cer should be clarified in further studies.
